Skip to Main Content

Can an app replace in-person therapy? Is Illumina too big to Grail? And is another CRISPR patent dispute in the cards?

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Mario Aguilar joins us to discuss a fascinating experiment in Nevada, where one city is giving its residents free access to a therapy app — and getting a mixed reception. Then, New York University antitrust expert Eleanor Fox calls in to discuss the case of Illumina, the genome sequencing giant whose grand plans keeping running afoul of the Federal Trade Commission. Finally, we embark on a lightning round, covering the latest Covid-19 vaccine news, biotech’s biggest events over the next three months, and the death of a pioneering Gilead Sciences executive.


For more on what we cover, here’s the Talkspace story; here’s more on Illumina; here’s a preview of the quarter to come; and here’s the latest genome-editing spat; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the coronavirus pandemic.

Be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].